Latest 10-K annual reports

NASDAQ
Viant Technology Inc. filed an amendment to its 2024 Annual Report on Form 10-K to include management's assessment of effective internal control over financial reporting.
NYSE
HP Inc. reported a 3.2% increase in total net revenue for fiscal year 2025, driven by Personal Systems unit volume growth and services, despite declines in Printing revenue and higher commodity costs, leading to a decrease in net earnings and diluted EPS.
NASDAQ
DLH Holdings Corp. reported a significant revenue decrease for fiscal year 2025, primarily due to the conversion of key government contracts to small business contractors, impacting net income and EBITDA.
NASDAQ
Amtech Systems, Inc. reported a substantial net loss and revenue decline in fiscal year 2025, primarily due to a prolonged semiconductor market contraction and significant asset impairments.
OQB
Genvor Incorporated, a pioneer in AI-accelerated peptide technology for sustainable agriculture, reported a significant net loss for fiscal year 2025 while advancing its proprietary BioCypher Algorithm and securing a Bayer Golden Ticket award.
REV Group, a specialty vehicle manufacturer, reported a significant increase in Adjusted EBITDA for fiscal year 2025, driven by its Specialty Vehicles segment, while also announcing a proposed merger with Terex Corporation.
NASDAQ
Flux Power Holdings, Inc. filed an amendment to its annual report, disclosing executive and board changes, updated compensation, and details of a recent $5.0 million private placement.
OQB
Zapata Quantum reports significant 2024 losses, temporary operational suspension, and a strategic pivot in 2025 to refocus on its core hardware-agnostic quantum software mission, alongside ongoing debt restructuring and capital raising efforts.
AMEX
Gencor Industries, Inc. reported a 2.0% increase in net revenue and higher net income for fiscal year 2025, despite identified material weaknesses in internal control over financial reporting and a significant drop in backlog.
NASDAQ
Timberland Bancorp, Inc. announced a 20.1% increase in net income for fiscal year 2025, driven by higher net interest income and loan growth, while maintaining strong capital ratios.
NYSE
Star Group, L.P. announced a significant increase in net income and Adjusted EBITDA for fiscal year 2025, fueled by strategic acquisitions and colder weather conditions.
NYSE
Compass Diversified Holdings has restated its financial statements for 2022-2024 due to fraud at its Lugano subsidiary, leading to material control weaknesses and substantial doubt about its ability to continue as a going concern.
AB International Group Corp. filed an amendment to its annual report to include auditor consent, which highlights a going concern issue for the company.
SRx Health Solutions Inc. has completed a reverse merger, discontinuing its Canadian healthcare operations to focus solely on its Halo pet health and wellness business, despite reporting significant losses.
OQX
Janel Corporation announced a significant increase in net income and revenues for fiscal year 2025, driven by strong performance in its Logistics segment and strategic acquisitions across all business units.
NASDAQ
The Cooper Companies reported a 5% increase in fiscal year 2025 net sales to $4.09 billion, driven by CooperVision, but saw a 3% decline in operating income and a 63% drop in CooperSurgical's operating income.
NYSE
Hormel Foods experienced a significant decline in net earnings for fiscal 2025 due to substantial impairment charges and persistent inflation, despite overall sales growth.
NASDAQ
Inotiv, Inc. reported increased revenue but faces substantial doubt about its ability to continue as a going concern due to significant debt maturities, forecasted covenant non-compliance, and ongoing legal and cybersecurity challenges.
NASDAQ
Azenta, Inc. reported a net income from continuing operations of $24.5 million for fiscal year 2025, a significant improvement from a $24.4 million loss in the prior year, despite ongoing internal control weaknesses and a substantial loss from discontinued operations.
NASDAQ
Armada Acquisition Corp. II, a SPAC, has entered into a definitive business combination agreement with Pathfinder Digital Assets LLC and Ripple Labs Inc., aiming to become a publicly traded company focused on FinTech, SaaS, and AI.
NASDAQ
RGC Resources, Inc. announced a 13% increase in net income and a higher dividend per share for fiscal year 2025, driven by rate increases and record natural gas deliveries.
NASDAQ
Hennessy Advisors, Inc. reported a significant increase in net income for fiscal year 2025, driven by higher average assets under management, despite overall AUM decline.
AMEX
Pineapple Financial Inc. reported a narrower net loss for fiscal year 2025, driven by increased mortgage originations and cost efficiencies, while strategically expanding into digital assets and insurance.
NYSE
Vestis Corporation reported a net loss of $40.2 million for fiscal year 2025 on declining revenue, while initiating a multi-year business transformation and restructuring plan aimed at improving profitability and cash flow.
NASDAQ
Simulations Plus, Inc. reported a net loss of $64.7 million for fiscal year 2025, primarily driven by $77.2 million in impairment charges related to underperforming acquisitions and a stock price decline.
NASDAQ
Jewett-Cameron Trading Co. Ltd. reported a significant net loss of $4.1 million for fiscal year 2025, driven by new global tariffs, supply chain disruptions, and weak demand in its pet product segment.
AB International Group Corp. reports increased revenue and net income for fiscal 2025, alongside a significant working capital deficit and plans for a reverse stock split and name change to AI Era Corp.
NYSE
ESCO Technologies Inc. reported significant revenue and earnings growth in fiscal year 2025, driven by strategic acquisitions and the divestiture of its Space business, while expanding its backlog by over 70%.
OTC.Pink
VitaSpring Biomedical Co. Ltd. reported a net loss of $4.16 million for the fiscal year ended January 31, 2023, a significant decline from the prior year's profit, as it focuses on R&D and seeks additional capital.
OID
CNBX Pharmaceuticals Inc. reported no revenue for the fiscal year ended August 31, 2025, with a net loss of $313,976, and auditors expressing substantial doubt about its ability to continue as a going concern.